Business
Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials
Fourth Quarter 2022 Fourth quarter 2022 revenue is expected to be in a range of $397 million to $398 million, representing a decrease of approximately 2% on a
About this update from Integra Lifesciences Holdings Corporation
[{"type":"text","content":"Fourth Quarter 2022 Fourth quarter 2022 revenue is expected to be in a range of $397 million to $398 million, representing a decrease of approximately 2% on a reported basis and an increase of approximately 3% on an organic basis compared to 2021. Fourth quarter 2022 adjusted earnings per diluted share is expected to be above the high end of the Company’s October guidance range. Full-Year 2022 Full-year 2022 revenue is expected to be in a range of $1,557 million to $1,558 million, representing an increase of approximately 1% on a reported basis and an increase of approximately 4% on an organic basis compared to 2021.Full-year quarter 2022 adjusted earnings per diluted share is expected to be above the high end of the Company’s October guidance range. PRINCETON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2022 financial results. Preliminary Fourth Quarter and Full-Year 2022 Revenue and Adjusted Earnings Per Diluted Share Fourth quarter 2022 revenue is expected to be in the range of $397 million to $398 million, representing a decrease of approximately 2% on a reported basis and an increase of approximately 3% on an organic basis compared to the prior year. Revenue is in line with the outlook the Company provided in October. Fourth quarter 2022 adjusted earnings per diluted share is expected to be above the high end of the Company’s October guidance range. The Company expects full-year 2022 reported revenue to be in the range of $1,557 million to $1,558 million, representing an increase of approximately 1% on a reported basis and an increase of approximately 4% on an organic basis. Full-year quarter 2022 adjusted earnings per diluted share is expected to be above the high end of our October guidance range and above the mid-point of the Company’s original February guidance range. The preliminary results set forth above are unaudited and remain subject to completion of the Company’s financial closing procedures. For further information regarding the Company's use of adjusted earnings per diluted share, a non-GAAP financial measure, please refer to the discussion of non-GAAP financial measures contained herein. “I am pleased with our fourth quarter and full year ...